Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT06690736
Recruiting Not applicable

Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases

NCT06690736 · tracked via the Priya Life Science China tracker
Sponsor
Tianjin Medical University
Phase
Not applicable
Started
2022-03-01
Last updated
2026-09-08

Condition(s) studied

CXCR4-related DiseaseTumorPositron Emission TomographyMetastasis

Investigational drug(s) / intervention(s)

CXCR4 PET/CT Imaging

CXCR4 PET/CT Imaging: Each subject receive a single intravenous injection of 68Ga/18F-Pentixafor/Pentixather, and undergo PET/CT imaging within the specificed time.

Study summary

To evaluate the potential usefulness of 68Ga/18F-Pentixafor/Pentixather positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various CXCR4-related disease patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: * suspected or confirmed untreated Lymphoproliferative and other CXCR4-related diseases patients * 18F-FDG PET/CT within two weeks * signed written consent. Exclusion Criteria: * pregnancy * breastfeeding * known allergy against Pentixafor

Primary outcome measure(s)

  • Standardized uptake value (SUV) — 30 days
    Standardized uptake value (SUV) of FAPI for each target lesion of subject or suspected primary tumor or/and metastasis.

Trial sites (3)

FacilityCityRegionStatus
The First Affiliated Hospital of University of Science and Technology of China Hefei Anhui Recruiting
The Affiliated Hospital of Qingdao University Qingdao Shandong Recruiting
Tianjin Medical University General Hospital Tianjin Tianjin Municipality Recruiting

More Tianjin Medical University trials in China

ALI & Pulmonary HA Deposition After SAH Recruiting
Beta Amyloid PET/CT in Various Aβ-Related Disease Recruiting
SNRK & Vascular Endothelial Aging Recruiting
An Interventional Study of Upadacitinib Extended-Release Tablets in Patients With Refractory Uveitis Active, not recruiting
Monoamine Oxidase A PET/CT in Various MAO-A-Related Disease Recruiting

Other trials for the same condition

Research on NI-FAPI-04 for the Treatment of Hypoxic and Fibroblast Activation Protein Related Tumors Enrolling by invitation
Study of Peripheral Blood CHI3L1 to Predict Tumor Response to Radiotherapy Starting soon
Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases. Recruiting
Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer Recruiting
Integrative Analysis of CRC Liver Metastasis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06690736 on ClinicalTrials.gov ↗ ← All trials in China